Secukinumab

Patients treated with secukinumab for papulopustular rosacea saw significant improvements in quality of life and reduction of severity markers, according to a study presented at the American Academy of Dermatology virtual meeting.

Taltz was found to be more effective at improving signs and symptoms among patients with moderate to severe plaque psoriasis than Tremfya, according to a multicenter, randomized, double-blind, parallel-group, phase 4 study.

Ilumya is among the most cost-effective first-line therapies for treating psoriasis, according to research presented by Justin Carrico, MD, of RTI Health Solutions, and colleagues at Academy of Managed Care Pharmacy Nexus.

Patients with psoriasis prescribed biologic agents are less likely to develop psychiatric illnesses compared with patients not prescribed biologic agents, which researchers concluded is due to treatment selection bias.